Switching to teclistamab was utilized as an early treatment strategy in a patient with cardiac AL amyloidosis who had a suboptimal response to first-line Dara-CyBorD.
This case report describes the use of teclistamab in a patient with cardiac AL amyloidosis following a suboptimal response to first-line Dara-CyBorD therapy.
Absolute Event Rate: 0% vs 0%
We present a case of a 67-year-old man with cardiac AL amyloidosis who achieved only a partial hematologic response after one cycle of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (...
Liu et al. (Wed,) reported a other. Switching to teclistamab was utilized as an early treatment strategy in a patient with cardiac AL amyloidosis who had a suboptimal response to first-line Dara-CyBorD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: